Cyslabdan, a new potentiator of imipenem activity against methicillin-resistant Staphylococcus aureus, produced by Streptomyces sp. K04-0144. II. Biological activities.
Cyslabdan produced by Streptomyces sp. K04-0144 was found to potentiate imipenem activity against methicillin-resistant Staphylococcus aureus (MRSA). The MIC value of imipenem against MRSA was reduced from 16 to 0.015 microg/ml in combination with cyslabdan. Study on anti-MRSA activity of other typical antibiotics in combination with cyslabdan showed that the potentiating activity was limited to beta-lactam antibiotics. Furthermore, among beta-lactam antibiotics, the activity of carbapenems was most remarkably potentiated by cyslabdan.
Fukumoto
Atsushi
A
Kitasato Institute for Life Sciences and Graduate School of Infection Control Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, Japan.
Kim
Yong-Pil
YP
Hanaki
Hideaki
H
Shiomi
Kazuro
K
Tomoda
Hiroshi
H
Omura
Satoshi
S
D000111:Acetylcysteine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000096:biosynthesis / Q000494:pharmacology*; D015780:Carbapenems / Q000008:administration & dosage; D004224:Diterpenes / Q000008:administration & dosage* / Q000378:metabolism / Q000494:pharmacology*; D004357:Drug Synergism; D006801:Humans; D015378:Imipenem / Q000008:administration & dosage*; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D015394:Molecular Structure; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D013302:Streptomyces / Q000378:metabolism*; D047090:beta-Lactams / Q000008:administration & dosage
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D004224:Diterpenes; D047090:beta-Lactams; C529277:cyslabdan; D015378:Imipenem; D000111:Acetylcysteine